Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy
| Autor: | Ferdinandus, Justin, Metzenmacher, Martin, Kessler, Lukas, Umutlu, Lale, Aigner, Clemens, Karl, Kambartel Otto, Grünwald, Viktor, Eberhardt, Wilfried, Fendler, Wolfgang Peter, Herrmann, Ken, Faehling, Martin, Christoph, Daniel Christian |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Clinical/Translational Cancer Immunotherapy
Medizinische Fakultät » Universitätsklinikum Essen » Innere Klinik (Tumorforschung) Medizinische Fakultät » Universitätsklinikum Essen » Klinik für Nuklearmedizin Medizin Neoplasms. Tumors. Oncology. Including cancer and carcinogens lung neoplasms Medizinische Fakultät » Universitätsklinikum Essen » Kliniken Essen-Mitte programmed cell death 1 receptor PET Medizinische Fakultät » Universitätsklinikum Essen » Institut für Diagnostische und Interventionelle Radiologie und Neuroradiologie ddc:610 immunotherapy RC254-282 Medizinische Fakultät » Universitätsklinikum Essen » Klinik für Urologie |
| Zdroj: | Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021) Journal for Immunotherapy of Cancer |
| ISSN: | 2051-1426 |
| Popis: | Introduction Immunotherapy is the new standard of care in advanced nonsmall cell lung cancer (NSCLC). Recently published data show that treatment discontinuation after 12 months of nivolumab treatment is associated with shorter survival. Therefore, the ideal duration of immunotherapy remains unclear, and finding markers of beneficial outcomes is of great importance. Here, we determine the proportion of complete metabolic responses (CMR) in patients who have not progressed after 24 months of immunotherapy. Methods This is a retrospective analysis of 45 patients with positron emission tomography using 2-[18F]fluoro-2-deoxy-D-glucose imaging for assessment of residual metabolic activity after at least 24 months. CMR was defined as uptake in tumor lesions below background levels, using mediastinum as a reference. Results Out of 45 patients, 29 patients had a CMR (64%). CMR was observed more frequently in non-first-line patients. Patients with CMR were younger (median 65.7 vs 75.5, p=0.03). Fourteen patients with CMR have discontinued therapy and have not progressed until time of analysis; however, median follow-up was only 5.6 (range 0.8-17.0) months. Conclusion After a minimum of 24 months of palliative immunotherapy for NSCLC, CMR occurred in almost two thirds of patients. Potentially, achievement of CMR might identify patients, for whom palliative immunotherapy may be safely discontinued. OA Förderung 2021 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|